Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (IS): 2024-2025

Historic Depreciation & Amortization (IS) for Amphastar Pharmaceuticals (AMPH) over the last 2 years, with Sep 2025 value amounting to $14.1 million.

  • Amphastar Pharmaceuticals' Depreciation & Amortization (IS) rose 5.44% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year change of. This contributed to the annual value of $53.0 million for FY2024, which is 39.26% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Depreciation & Amortization (IS) stood at $14.1 million, which was down 3.33% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Depreciation & Amortization (IS) ranged from a high of $14.6 million in Q2 2025 and a low of $13.0 million during Q1 2024.
  • Over the past 2 years, Amphastar Pharmaceuticals' median Depreciation & Amortization (IS) value was $13.4 million (recorded in 2024), while the average stood at $13.6 million.
  • Data for Amphastar Pharmaceuticals' Depreciation & Amortization (IS) shows a peak YoY increased of 11.17% (in 2025) over the last 5 years.
  • Over the past 2 years, Amphastar Pharmaceuticals' Depreciation & Amortization (IS) (Quarterly) stood at $13.4 million in 2024, then climbed by 5.44% to $14.1 million in 2025.
  • Its Depreciation & Amortization (IS) stands at $14.1 million for Q3 2025, versus $14.6 million for Q2 2025 and $13.6 million for Q1 2025.